The IB Fund Manager is launching an Asia Pacific Healthcare Fund. The Fund will follow on from the IB Australian Bioscience Fund I in strategy and investment style.

Fund II is targeting $200m FUM.

Fund II will be a closed end fund, investing for up to 5 years in ‘later stage’ private and public Healthcare & Medical Science companies from the Australasia/Asia Pacific region and exiting investments, principally by trade sale, into the next ‘up to 5 years’.